Literature DB >> 18049473

The way forward in HCV treatment--finding the right path.

Michael P Manns1, Graham R Foster, Jürgen K Rockstroh, Stefan Zeuzem, Fabien Zoulim, Michael Houghton.   

Abstract

Infection with the hepatitis C virus (HCV) represents an important health-care problem worldwide. The prevalence of HCV-related disease is increasing, and no vaccine is yet available. Since the identification of HCV as the causative agent of non-A, non-B hepatitis, treatment has progressed rapidly, but morbidity and mortality rates are still predicted to rise. Novel, more efficacious and tolerable therapies are urgently needed, and a greater understanding of the viral life cycle has led to an increase in the number of possible targets for antiviral intervention. Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18049473     DOI: 10.1038/nrd2411

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  64 in total

Review 1.  Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.

Authors:  Paul Y Kwo; Maaz B Badshah
Journal:  Curr Gastroenterol Rep       Date:  2015-10

2.  In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Authors:  Oliver Lenz; Thierry Verbinnen; Tse-I Lin; Leen Vijgen; Maxwell D Cummings; Jimmy Lindberg; Jan Martin Berke; Pascale Dehertogh; Els Fransen; Annick Scholliers; Katrien Vermeiren; Tania Ivens; Pierre Raboisson; Michael Edlund; Susan Storm; Lotta Vrang; Herman de Kock; Gregory C Fanning; Kenneth A Simmen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 3.  Advances in nucleoside monophosphate prodrugs as anti-HCV agents.

Authors:  Drew R Bobeck; Raymond F Schinazi; Steven J Coats
Journal:  Antivir Ther       Date:  2010

Review 4.  Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.

Authors:  Li-Ping Chen; Jun Zhao; Yan Du; Yi-Fang Han; Tong Su; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Virol       Date:  2012-12-12

Review 5.  Hepatitis in 2010: the dawn of a new era in HCV therapy.

Authors:  Sandra Ciesek; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

6.  In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.

Authors:  Tse-I Lin; Oliver Lenz; Gregory Fanning; Thierry Verbinnen; Frédéric Delouvroy; Annick Scholliers; Katrien Vermeiren; Asa Rosenquist; Michael Edlund; Bertil Samuelsson; Lotta Vrang; Herman de Kock; Piet Wigerinck; Pierre Raboisson; Kenneth Simmen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

Review 7.  [Viral hepatitis B und C].

Authors:  Markus Reiser
Journal:  Med Klin (Munich)       Date:  2009-05-16

8.  Selection of cyclic peptide aptamers to HCV IRES RNA using mRNA display.

Authors:  Alexander Litovchick; Jack W Szostak
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-29       Impact factor: 11.205

9.  HCV antibody response and genotype distribution in different areas and races of China.

Authors:  Leili Jia; Jiyun Yu; Jinliang Yang; Hongbin Song; Xuelin Liu; Yong Wang; Yuanyong Xu; Chuanfu Zhang; Yanwei Zhong; Qiao Li
Journal:  Int J Biol Sci       Date:  2009-06-13       Impact factor: 6.580

Review 10.  Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

Authors:  Martin Stürmer; Hans Wilhelm Doerr; Lutz Gürtler
Journal:  Med Microbiol Immunol       Date:  2009-06-04       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.